KORU Medical Systems (KRMD) Stock Price
KORU Medical Systems Price
Revenue has compounded at 18.1% per year over the past 19 years to 41.13 M USD. Earnings per share have declined at 6.5% per year over the last 11 years. KORU Medical Systems's net margin stands at -6.4%, up from -19.4% several years earlier. Analysts set a median price target of 6.00 USD, implying 101.3% above the current price. Of 10 analysts, 8 rate the stock a buy — an overall Buy consensus.
KORU Medical Systems stock price
KORU Medical Systems business model & stock analysis
Frequently asked questions about KORU Medical Systems
The business model of Repro Med Systems Inc is focused on the development, manufacturing, and marketing of innovative medical devices. The company specializes in the design of proprietary infusion technologies, primarily catering to patients with chronic diseases and conditions. Repro Med Systems Inc aims to provide superior and convenient solutions for patients requiring infusion therapy, resulting in improved quality of life and enhanced healthcare outcomes. With their expertise in the field, the company continually strives to meet the evolving needs of patients and healthcare professionals alike, positioning itself as a leader in the medical device industry.
Repro Med Systems Inc, also known as RMS Medical Products, primarily operates in the medical devices industry. With a focus on innovative medical solutions, RMS specializes in the development, manufacture, and distribution of portable and easy-to-use medical devices. These devices primarily assist with the administration of fluids and medications in various healthcare settings. The company's products, like the Freedom Syringe Infusion System, are designed to enhance patients' quality of life by providing effective and convenient treatment options. As a leader in this industry, Repro Med Systems Inc continues to provide cutting-edge solutions that positively impact healthcare delivery.
The main competitors of Repro Med Systems Inc in the market include other medical device companies such as Becton, Dickinson and Company (BD), Baxter International Inc., and Teleflex Incorporated. These companies also offer a range of medical devices and solutions, competing with Repro Med Systems Inc in the same market segment.
Repro Med Systems Inc, commonly known as RMS Medical Products, is a leading medical device company specializing in the development and commercialization of advanced infusion solutions. With a rich history spanning over 30 years, RMS has established itself as a trusted provider of innovative medical products that improve patient outcomes. The company's flagship product, the FREEDOM Syringe Infusion System, revolutionizes the way medication is delivered, offering patients a convenient and effective alternative to traditional infusion methods. As a pioneer in the industry, Repro Med Systems Inc continues to invest in research and development, ensuring its products remain at the forefront of medical advancements.
Repro Med Systems Inc, a renowned medical device company, has achieved significant milestones throughout its existence. Over the years, the company has successfully developed and marketed innovative medical products, firmly establishing itself as a leader in the industry. Repro Med Systems Inc has gained recognition for its proprietary technology, particularly its market-leading primary product, the FREEDOM60® and FreedomEdge™ Syringe Infusion Systems. These devices have revolutionized the way patients receive medication, offering enhanced convenience, safety, and precision. With a strong commitment to research and development, Repro Med Systems Inc has continually expanded its product portfolio, meeting the evolving needs of healthcare providers and patients alike.
Repro Med Systems Inc, also known as RMS Medical Products, is primarily present in various countries and regions worldwide. The company operates globally, with a significant presence in North America, including the United States and Canada. Additionally, Repro Med Systems Inc has extended its reach to several international markets, such as Europe, particularly in the United Kingdom, Germany, France, Italy, and Spain. Moreover, the company has established a strong presence in the Asia-Pacific region, including Japan, China, and Australia. With its global presence, Repro Med Systems Inc serves a diverse customer base across different continents.
Repro Med Systems Inc, a leading stock in the healthcare sector, represents core values of innovation, excellence, and dedication to patient care. With their robust corporate philosophy, Repro Med Systems Inc strives to provide cutting-edge medical devices and solutions that enhance the quality of life for patients. The company's mission revolves around delivering safe, reliable, and efficient medical technologies, ensuring positive medical outcomes and improving patient experiences. Repro Med Systems Inc's commitment to customer satisfaction, continuous improvement, and ethical business practices truly sets them apart in the industry. By embracing these values, Repro Med Systems Inc establishes itself as a trusted and valued healthcare provider.
Analysts currently set an average price target of 6.00 USD for the KORU Medical Systems stock (median: 6.00 USD), implying +101.3 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the KORU Medical Systems stock: 8 recommend buying, 2 holding and 0 selling. For 2026, analysts expect KORU Medical Systems to generate revenue of 48.04 M USD and earnings per share of -0.04 USD.
Converted at the current exchange rate, the KORU Medical Systems share trades at 2.66 EUR (2.98 USD).
The KORU Medical Systems share (KRMD) is listed on 1 stock exchanges, including: NASDAQ (KRMD).
Repro Med Systems Inc (RMS) is a leading provider of medical devices and consumables for infusion and pain therapy. The company was founded in 1980 and is headquartered in Chester, New York. RMS's business model focuses on three main areas: infusion pumps, pain therapy systems, and consumables. One of RMS's key product lines is infusion pumps. The company offers a wide range of portable and stationary infusion pumps used in the administration of fluids and medications to patients. These devices enable accurate dosing and monitoring of infusions, contributing to the safety and effectiveness of treatment. Another important area for RMS is pain therapy. The company offers systems for controlled pain delivery, allowing effective pain relief for patients with acute or chronic pain. RMS provides both portable and stationary pain therapy systems that enable accurate dosing and individual adjustment of pain medications. Consumables such as catheters, syringes, and tubes are also an important part of RMS's offering. The company provides high-quality and reliable products specifically designed for use with their infusion pumps and pain therapy systems. RMS focuses on developing and marketing innovative medical devices and consumables that contribute to the quality and efficiency of patient care. The company works closely with physicians, nurses, and other healthcare providers to understand patient needs and provide the best possible solutions. The company sells its products in the US and worldwide through a network of dealers, distributors, and online platforms. RMS has a strong presence in North America but also operates in Europe, Asia, and other regions. The company places great value on customer satisfaction and offers comprehensive customer support and training. Overall, RMS is an established and successful provider of medical devices and consumables for infusion and pain therapy. The company benefits from a strong market position, innovative products, and an experienced management team. With its broad product line and strong distribution network, RMS is well positioned to continue growing and expanding in the future.
The expected revenue of KORU Medical Systems is 48.04 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of KORU Medical Systems is -1.80 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of KORU Medical Systems is currently -76.26. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the KORU Medical Systems stock.
The price-to-sales ratio (P/S) of KORU Medical Systems is currently 2.87. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the KORU Medical Systems stock.
The Eulerpool Quality Score for KORU Medical Systems is 2/10.
The ISIN of KORU Medical Systems is US7599101026. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of KORU Medical Systems is 913004. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of KORU Medical Systems is KRMD. The ticker symbol is used to trade KORU Medical Systems shares on the stock exchange.
KORU Medical Systems stock
KORU Medical Systems Peer Group
KORU Medical Systems Ticker
KORU Medical Systems FIGI
All fundamentals and in-depth analysis of KORU Medical Systems
Our stock analysis for KORU Medical Systems stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of KORU Medical Systems. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.